NO20012981L - Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme - Google Patents

Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme

Info

Publication number
NO20012981L
NO20012981L NO20012981A NO20012981A NO20012981L NO 20012981 L NO20012981 L NO 20012981L NO 20012981 A NO20012981 A NO 20012981A NO 20012981 A NO20012981 A NO 20012981A NO 20012981 L NO20012981 L NO 20012981L
Authority
NO
Norway
Prior art keywords
compositions
active ingredient
biodegradable polymer
solid solution
useful
Prior art date
Application number
NO20012981A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012981D0 (no
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20012981D0 publication Critical patent/NO20012981D0/no
Publication of NO20012981L publication Critical patent/NO20012981L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
NO20012981A 1998-12-16 2001-06-15 Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme NO20012981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (2)

Publication Number Publication Date
NO20012981D0 NO20012981D0 (no) 2001-06-15
NO20012981L true NO20012981L (no) 2001-07-27

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012981A NO20012981L (no) 1998-12-16 2001-06-15 Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme

Country Status (35)

Country Link
EP (1) EP1140026B1 (xx)
JP (1) JP4759141B2 (xx)
KR (1) KR100707710B1 (xx)
CN (1) CN1195497C (xx)
AP (1) AP1769A (xx)
AR (1) AR021652A1 (xx)
AT (1) ATE303795T1 (xx)
AU (1) AU770673B2 (xx)
BG (1) BG65500B1 (xx)
BR (1) BR9916276A (xx)
CA (1) CA2355077C (xx)
CR (1) CR6424A (xx)
CZ (1) CZ301947B6 (xx)
DE (1) DE69927177T2 (xx)
DK (1) DK1140026T3 (xx)
EA (1) EA004502B1 (xx)
EE (1) EE200100314A (xx)
ES (1) ES2245128T3 (xx)
HK (1) HK1041645B (xx)
HR (1) HRP20010446A2 (xx)
HU (1) HU226586B1 (xx)
ID (1) ID28909A (xx)
IL (2) IL143761A0 (xx)
ME (2) ME00066B (xx)
NO (1) NO20012981L (xx)
NZ (1) NZ511962A (xx)
OA (1) OA11728A (xx)
PL (1) PL196822B1 (xx)
RS (1) RS50123B (xx)
SK (1) SK285812B6 (xx)
TR (1) TR200101759T2 (xx)
TW (1) TWI221418B (xx)
UA (1) UA73101C2 (xx)
WO (1) WO2000035423A1 (xx)
ZA (1) ZA200104899B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
DE50210646D1 (de) 2001-05-23 2007-09-20 Hexal Ag Verfahren zur herstellung von implantaten mittels lösungsmittelfreier herstellung eines homogenisats
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
ES2536460T3 (es) * 2004-09-21 2015-05-25 Shandong Luye Pharmaceutical Co., Ltd. Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2586439T3 (es) * 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
US11672755B2 (en) * 2019-12-31 2023-06-13 Wanka Tanka Ltd. Extended release plastic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (xx) * 1989-07-28 1992-01-15 Debiopharm Sa
ATE226091T1 (de) * 1990-05-16 2002-11-15 Southern Res Inst Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
ATE114467T1 (de) * 1990-06-01 1994-12-15 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol.
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
AU770673B2 (en) 2004-02-26
PL196822B1 (pl) 2008-02-29
SK285812B6 (sk) 2007-08-02
ZA200104899B (en) 2002-09-16
CZ301947B6 (cs) 2010-08-11
DK1140026T3 (da) 2006-01-02
WO2000035423A1 (en) 2000-06-22
PL348233A1 (en) 2002-05-20
TWI221418B (en) 2004-10-01
HRP20010446A2 (en) 2002-06-30
CA2355077C (en) 2009-05-26
DE69927177D1 (de) 2005-10-13
YU41401A (sh) 2003-12-31
CR6424A (es) 2004-02-26
ATE303795T1 (de) 2005-09-15
HK1041645A1 (en) 2002-07-19
BR9916276A (pt) 2001-09-04
OA11728A (en) 2005-02-01
IL143761A (en) 2006-08-01
ES2245128T3 (es) 2005-12-16
NO20012981D0 (no) 2001-06-15
BG105591A (en) 2002-01-31
TR200101759T2 (tr) 2001-12-21
AP2001002198A0 (en) 2001-09-30
WO2000035423A9 (en) 2002-08-22
EP1140026B1 (en) 2005-09-07
JP2002532408A (ja) 2002-10-02
IL143761A0 (en) 2002-04-21
ME00066B (me) 2010-06-10
BG65500B1 (bg) 2008-10-31
MEP19408A (en) 2010-06-10
EP1140026A1 (en) 2001-10-10
DE69927177T2 (de) 2006-06-08
UA73101C2 (en) 2005-06-15
NZ511962A (en) 2003-06-30
CA2355077A1 (en) 2000-06-22
AU1742500A (en) 2000-07-03
HK1041645B (zh) 2005-07-29
JP4759141B2 (ja) 2011-08-31
KR100707710B1 (ko) 2007-04-18
EE200100314A (et) 2002-08-15
CZ20012157A3 (cs) 2001-09-12
SK8282001A3 (en) 2001-11-06
HU226586B1 (en) 2009-04-28
AP1769A (en) 2007-08-22
ID28909A (id) 2001-07-12
RS50123B (sr) 2009-03-25
KR20010082359A (ko) 2001-08-29
HUP0105048A2 (hu) 2002-05-29
HUP0105048A3 (en) 2002-09-30
CN1330536A (zh) 2002-01-09
EA200100551A1 (ru) 2001-10-22
CN1195497C (zh) 2005-04-06
AR021652A1 (es) 2002-07-31
EA004502B1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
NO20012981L (no) Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme
JP6530845B2 (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法
US20210212934A1 (en) Methods for providing long-lasting anesthetic effect using microparticles
CA2474698A1 (en) Polymer-based compositions for sustained release
KR20080043852A (ko) 신규 투여 제형
CA2182593A1 (en) Oral liquid compositions containing paroxetine resinate
RU2006147244A (ru) Способ составления быстро диспергируемых лекарственных форм, содержащих по меньшей мере один рыбий желатин, который выбирают на основе молекулярной массы
DE202006018608U1 (de) Buprenorphin-Wafer zur Drogensubstitutionstherapie
JPH062672B2 (ja) パーキンソン疾患治療用薬剤
NZ592339A (en) Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
TW200835524A (en) Solid dispersion composition
EP0214058A2 (fr) Composition pharmaceutique contenant des dérivés de l'histamine
JPH10508029A (ja) 不安を治療する方法
KR20090048463A (ko) 장기간에 걸쳐 활성원을 방출하는 피하 이식제
JP2012516303A (ja) ２−オキソ−１−ピロリジン誘導体を含む医薬組成物
JP2004502729A (ja) Ｓｓｒｉおよびエストロゲン剤の組み合わせ
EP2595607A2 (de) Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
US20020019392A1 (en) Methods of treating neuropeptide Y-related conditions
WO2017003186A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
JP2022548349A (ja) 医薬製剤
CA2345406A1 (en) Analgesic
US6369051B1 (en) Combinations of SSRI and estrogenic agents
CN105384676A (zh) 三重再摄取抑制剂及其应用方法
JP2003503459A (ja) パラセタモール及びブスピロンを含有した鎮痛性作用を有する新規医薬組成物
JP2001187737A (ja) 聴力改善剤

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application